Skip to main content
Premium Trial:

Request an Annual Quote

Celera Claims Progress in Establishing Operations

Premium

NORWALK, Conn.--Perkin-Elmer's third-quarter results announcement last month pointed to positive developments at its Celera Genomics group. By the end of April, Celera had 300 employees and laboratories and related facilities were almost fully built. The company's staff has begun sequencing the Drosophila melanogaster genome and the unit is cooperating with Compaq Computer to build one of the world's largest supercomputing centers. Amgen, Pharmacia & Upjohn, and Novartis Pharma have all signed five-year subscription agreements to Celera databases.

Perkin-Elmer has received shareholder approval to reorganize its corporate structure and will change its name to PE Corporation. The revamp will also result in the creation of separate securities for its PE Biosystems group and Celera.

During the quarter ended March 31, PE Biosystems entered into a lease agreement with Celera for ABI Prism 3700 DNA Analyzers. Revenues from sales of those instruments to Celera were $5.2 million for the quarter.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.